The Effect of Mobilization With Movement on Pain and Function Among Patients With Knee Osteoarthritis

August 11, 2016 updated by: Imam Abdulrahman Bin Faisal University

Osteoarthritis (OA) is the most prevalent form of arthritis and is reported to be the most important reason behind functional disability and musculoskeletal disorders among aged individuals. OA is "a total joint failure; represented by pathological damage to articular cartilage, that affects bone, menisci, synovium, ligaments, and neuromuscular tissue". Knee OA could be responsible for pain and functional disability in 19.2% of individuals aged more than 45 years in the Framingham study and in 27.8% of such individuals in the Johnston County Osteoarthritis Project. However, in the third National Health and Nutrition Examination Survey (NHANES III), nearly 37% of individuals aged 60 years or older had radiographic knee OA. Oliveria et al. (1995) reported that age- and sex-standardized incidence rates of symptomatic hip, knee, and hand OA were 88, 240, and 100/100,000 person-years, respectively. In addition, the incidence rates of symptomatic OA of the knee, hand, or hip increased rapidly at age 50 and then levelled off beyond age 70. There were not enough data to report the prevalence of OA in Arabic countries. However, a cross-sectional study performed in Saudi Arabia demonstrated radiographic knee OA in 53.3% of men and 60.9% of women, while about 18% of women and 10% of men had symptomatic OA. Although it is well established that OA is mainly caused by damage occurring in the joint because of degeneration and inflammation, there is no known cure for OA and our understanding of the pathological aetiology of OA is still deficient and poorly understood.

The primary objective of this study is to investigate the immediate and the carry-over effect of MWM on pain and function in patients with knee OA. A secondary objective is to evaluate this effect among those patients who demonstrate features of central sensitization.

Study Overview

Status

Completed

Conditions

Detailed Description

Participants:

A power analysis was performed using G*Power 3.1 (F tests, analysis of variance [ANOVA]: repeated measure, within-between interaction, and a priori: compute required sample size). A result of 16 patients (treatment group = 8 and sham group = 8) was used to calculate an effect size (ES) of 0.27 for the pressure pain threshold of the knee after the intervention between groups. The power estimated for ANOVA for the two groups with a significance of 0.05 revealed that a total sample size of 27 patients was necessary to obtain a power of 0.80. Considering a 20% attrition rate, a minimum of 18 patients needed to be recruited for the first phase in this study.

Patients with knee OA who attended King Fahd Hospital of the University will be recruited for this study. Patients will be diagnosed at the orthopedic clinic and referred to the Department of Physiotherapy. Patients who are willing to participate in the study will be screened for their eligibility

Ethical considerations:

The study was approved by the Institutional Review Board (IRB) at the University of Dammam (IRB Number: IRB-2014-04-323). Eligible individuals for this study will be informed of the risks and benefits and will be asked to read and sign a written consent form.

Participant confidentiality will be maintained by using a code instead of the participant's name on the data collection form. All data collection forms will be saved in a file and secured in a locker. Only the researcher and the supervisor had a key to open this locker.

Statistical Analysis:

Data will be analyzed using International Business Machines (IBM) Statistical Package for Social Sciences (SPSS) for windows (version 20.0), significance level was set at p < 0.05.

In phase 1, patients characteristics between groups at baseline will be analyzed using an independent t-test. One way ANOVA with repeated measures will be used to analyze the differences for other parametric data, Bonferroni adjustment will be used to compare main effects. Post-hoc tests will be performed to reveal differences of within- between groups over time (baseline, immediately post intervention, and after 2 days of intervention). For Likert-scale WOMAC, the Mann-Whitney U test will be used to investigate between-group analysis. Whereas, the Wilcoxon test will be used for within-group analysis. Further analysis to reveal correlations between the outcome measures will be investigated using Pearson Correlation test.

In phase 2, the groups are matched in age, gender, and BMI. The related t-test will be used to investigate differences between the groups.

Study Type

Interventional

Enrollment (Actual)

38

Phase

  • Phase 1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Had unilateral or bilateral knee OA
  • Knee OA K&L grade ≥ 2
  • VAS = 3 cm over the previous 24 hours
  • Able to walk ≥ 6-meter distances with or without an aid

Exclusion Criteria:

  • Had knee or lower limb surgery
  • Oral corticosteroid use (current\ 4 weeks)
  • Altered sensation around knee and shoulder
  • Exhibited cognitive difficulties
  • Intra-articular corticosteroid or hyaluronic acid injection within 6 months
  • Had leg sciatica
  • Contraindication to manual therapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: MWM treatment

Mobilization with movement (MWM) is a combination of sustained passive accessory joint mobilization with an active or functional movement.

MWM will be applied (three sets of 10 repetitions) during active knee flexion and extension range of motion (ROM). The therapist initially will apply the pain-free manual glide force on the tibia with the knee resting in a mid-range position. The glide force will be sustained while the patient performed 10 repetitions of self-active full range knee flexion and extension; overpressure was included at the end range.

Other Names:
  • Mobilization with Movement, Manual therapy
Sham Comparator: MWM sham
The patients will be handled similarly to MWM treatment group, except that they will not receive directional glide; instead, the physiotherapist's hands are just touch the knee skin without pressure; one hand on the tibia while the other hand on the femur. However, available active knee flexion and extension ROM will be performed (three sets of 10 repetitions).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Visual Analog Scale (VAS)
Time Frame: Change from Baseline in Visual Analog Scale at Immediate post-intervention
Current pain intensity will be measured by a 10-cm line
Change from Baseline in Visual Analog Scale at Immediate post-intervention
The Visual Analog Scale (VAS)
Time Frame: Change from Baseline in Visual Analog Scale at 2 days
Current pain intensity will be measured by a 10-cm line
Change from Baseline in Visual Analog Scale at 2 days
Western Ontario and McMaster Universities (WOMAC) Index
Time Frame: Change from Baseline in WOMAC at 2 days
Self-administered questionnaire presented in Likert-scale format
Change from Baseline in WOMAC at 2 days
Self-Leeds Assessment of Neuropathic Symptoms and signs (S-LANSS) Scale
Time Frame: At Baseline
A clinical-based instrument for identifying patients whose pain is dominated by neuropathic mechanisms
At Baseline
Pressure Pain Threshold (PPT)
Time Frame: Change from Baseline in PPT at Immediate post-intervention
A digital pressure algometer will be used to quantify pain intensity in Kpa
Change from Baseline in PPT at Immediate post-intervention
Pressure Pain Threshold (PPT)
Time Frame: Change from Baseline in PPT at 2 days
A digital pressure algometer will be used to quantify pain intensity in Kpa
Change from Baseline in PPT at 2 days
Thermal Perception and Pain Thresholds
Time Frame: Change from Baseline in Thermal Perception and Pain Thresholds at Immediate post-intervention
A Thermotest System will be used to determine thermal thresholds in degree centigrade
Change from Baseline in Thermal Perception and Pain Thresholds at Immediate post-intervention
Thermal Perception and Pain Thresholds
Time Frame: Change from Baseline in Thermal Perception and Pain Thresholds at 2 days
A Thermotest System will be used to determine thermal thresholds in degree centigrade
Change from Baseline in Thermal Perception and Pain Thresholds at 2 days
Hand-Held Dynamometer
Time Frame: Change from Baseline in Hand-Held Dynamometer at Immediate post-intervention
A digital instrument will be used to examine isometric muscle strength of force development in pound
Change from Baseline in Hand-Held Dynamometer at Immediate post-intervention
Hand-Held Dynamometer
Time Frame: Change from Baseline in Hand-Held Dynamometer at 2 days
A digital instrument will be used to examine isometric muscle strength of force development for knee flexion and extension in pound
Change from Baseline in Hand-Held Dynamometer at 2 days
Standard Goniometer
Time Frame: Change from Baseline in Standard Goniometer at Immediate post-intervention
Active range of motion for knee flexion and extension in degree
Change from Baseline in Standard Goniometer at Immediate post-intervention
Standard Goniometer
Time Frame: Change from Baseline in Standard Goniometer at 2 days
Active range of motion for knee flexion and extension in degree
Change from Baseline in Standard Goniometer at 2 days
Three-meter Timed "Up and Go"
Time Frame: Change from Baseline in Three-meter Timed "Up and Go" at Immediate post-intervention
A walk test will be used to test a basic functional mobility
Change from Baseline in Three-meter Timed "Up and Go" at Immediate post-intervention
Three-meter Timed "Up and Go"
Time Frame: Change from Baseline in Three-meter Timed "Up and Go" at 2 days
A walk test will be used to test a basic functional mobility
Change from Baseline in Three-meter Timed "Up and Go" at 2 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Ali M Alshami, Ph.D, Imam Abdulrahman Bin Faisal University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2015

Primary Completion (Actual)

June 1, 2016

Study Registration Dates

First Submitted

August 8, 2016

First Submitted That Met QC Criteria

August 11, 2016

First Posted (Estimate)

August 12, 2016

Study Record Updates

Last Update Posted (Estimate)

August 12, 2016

Last Update Submitted That Met QC Criteria

August 11, 2016

Last Verified

August 1, 2016

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis

Clinical Trials on MWM Treatment

3
Subscribe